m3814

Stage III Pancreatic Cancer AJCC v8

National Cancer Institute (NCI)Phase 1/2Active

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 89/ 100

Competitive context

15 Active assets in the Stage III Pancreatic Cancer AJCC v8 cohort.

Asset / Sponsor	Phase	Rating
Letrozole OHSU Knight Cancer Institute	Phase 2	BB
Vinorelbine OHSU Knight Cancer Institute	Phase 2	BB
Abemaciclib OHSU Knight Cancer Institute	Phase 2	B
Telotristat Ethyl Emory University	Phase 2	B
Wild-Type Reovirus Northwestern University	Phase 2	B

View all 18 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant

CCC

Indicative ·

52 / 100

Unresectable Malignant Solid NeoplasmDormant

CCC

Indicative ·

50 / 100

Locally Advanced Unresectable Gallbladder CarcinomaDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.